| Identification | Back Directory | [Name]
FLLL31 | [CAS]
52328-97-9 | [Synonyms]
FLLL31
Tetramethylcurcumin
FLLL31 >=98% (HPLC)
FLLL31;FLLL-31;FLLL 31
(E,E)-1,7-Bis(3,4-dimethoxyphenyl)-4,4-dimethyl-1,6-heptadiene-3,5-dione
(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4,4-dimethyl-1,6-heptadiene-3,5-dione
1,6-Heptadiene-3,5-dione, 1,7-bis(3,4-dimethoxyphenyl)-4,4-dimethyl-, (1E,6E)- | [Molecular Formula]
C25H28O6 | [MDL Number]
MFCD19443859 | [MOL File]
52328-97-9.mol | [Molecular Weight]
424.49 |
| Chemical Properties | Back Directory | [Boiling point ]
594.5±50.0 °C(Predicted) | [density ]
1.140±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥10mg/mL | [form ]
powder | [color ]
yellow |
| Hazard Information | Back Directory | [Biological Activity]
Tetramethylcurcumin (FLLL31) is derived from curcumin and specifically inhibits phosphorylation of STAT3 by selectively binding to Janus kinase 2 and the STAT3 Src homology 2 domain. Tetramethylcurcumin has anti-inflammatory and anticancer effects. | [in vitro]
Tetramethylcurcumin (FLLL31; 2.5 and 5 μM; for 24 hours) downregulas STAT3 phosphorylation and DNA-binding activity in MDA-MB-231 breast and PANC-1 pancreatic cancer cells.
Tetramethylcurcumin inhibits cell viability , cell invasion. Tetramethylcurcumin is an effective inhibitor of STAT3 phosphorylation, DNA-binding activity, and transactivation in vitro, leading to the impediment of multiple oncogenic processes and the induction of apoptosis in pancreatic and breast cancer cell lines. | [target]
| [storage]
Store at -20°C |
|
|